vs

Side-by-side financial comparison of Invesco (IVZ) and OLIN Corp (OLN). Click either name above to swap in a different company.

Invesco is the larger business by last-quarter revenue ($1.7B vs $1.7B, roughly 1.0× OLIN Corp). OLIN Corp runs the higher net margin — -8.6% vs -58.9%, a 50.3% gap on every dollar of revenue. On growth, Invesco posted the faster year-over-year revenue change (6.2% vs -0.4%). Over the past eight quarters, Invesco's revenue compounded faster (7.1% CAGR vs 0.9%).

Invesco Ltd. is an American independent investment management company headquartered in Atlanta, Georgia, with branch offices in 20 countries. Its common stock is a constituent of the S&P 500 and trades on the New York Stock Exchange. Invesco operates under the Invesco, Invesco Perpetual, and Powershares brand names.

Olin Corporation is an American manufacturer of ammunition, chlorine, and sodium hydroxide. The company traces its roots to two companies, both founded in 1892: Franklin W. Olin's Equitable Powder Company and the Mathieson Alkali Works. Accidents at Olin chemical plants have exposed employees and nearby residents to health hazards.

IVZ vs OLN — Head-to-Head

Bigger by revenue
IVZ
IVZ
1.0× larger
IVZ
$1.7B
$1.7B
OLN
Growing faster (revenue YoY)
IVZ
IVZ
+6.6% gap
IVZ
6.2%
-0.4%
OLN
Higher net margin
OLN
OLN
50.3% more per $
OLN
-8.6%
-58.9%
IVZ
Faster 2-yr revenue CAGR
IVZ
IVZ
Annualised
IVZ
7.1%
0.9%
OLN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IVZ
IVZ
OLN
OLN
Revenue
$1.7B
$1.7B
Net Profit
$-995.9M
$-143.2M
Gross Margin
1.9%
Operating Margin
-86.2%
-9.4%
Net Margin
-58.9%
-8.6%
Revenue YoY
6.2%
-0.4%
Net Profit YoY
-575.8%
-1517.8%
EPS (diluted)
$-2.61
$-1.25

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IVZ
IVZ
OLN
OLN
Q4 25
$1.7B
$1.7B
Q3 25
$1.6B
$1.7B
Q2 25
$1.5B
$1.8B
Q1 25
$1.5B
$1.6B
Q4 24
$1.6B
$1.7B
Q3 24
$1.5B
$1.6B
Q2 24
$1.5B
$1.6B
Q1 24
$1.5B
$1.6B
Net Profit
IVZ
IVZ
OLN
OLN
Q4 25
$-995.9M
$-143.2M
Q3 25
$356.4M
$43.7M
Q2 25
$197.4M
$-2.8M
Q1 25
$171.1M
$1.2M
Q4 24
$209.3M
$10.1M
Q3 24
$55.0M
$-25.2M
Q2 24
$132.2M
$72.3M
Q1 24
$141.5M
$47.8M
Gross Margin
IVZ
IVZ
OLN
OLN
Q4 25
1.9%
Q3 25
10.7%
Q2 25
7.9%
Q1 25
9.0%
Q4 24
9.4%
Q3 24
8.5%
Q2 24
14.5%
Q1 24
12.7%
Operating Margin
IVZ
IVZ
OLN
OLN
Q4 25
-86.2%
-9.4%
Q3 25
16.5%
4.8%
Q2 25
14.1%
2.0%
Q1 25
18.1%
2.7%
Q4 24
19.6%
2.8%
Q3 24
6.6%
1.0%
Q2 24
13.9%
8.3%
Q1 24
14.4%
5.9%
Net Margin
IVZ
IVZ
OLN
OLN
Q4 25
-58.9%
-8.6%
Q3 25
21.7%
2.6%
Q2 25
13.0%
-0.2%
Q1 25
11.2%
0.1%
Q4 24
13.1%
0.6%
Q3 24
3.6%
-1.6%
Q2 24
8.9%
4.4%
Q1 24
9.6%
2.9%
EPS (diluted)
IVZ
IVZ
OLN
OLN
Q4 25
$-2.61
$-1.25
Q3 25
$0.66
$0.37
Q2 25
$-0.03
$-0.01
Q1 25
$0.38
$0.01
Q4 24
$0.46
$0.10
Q3 24
$0.12
$-0.21
Q2 24
$0.29
$0.62
Q1 24
$0.31
$0.40

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IVZ
IVZ
OLN
OLN
Cash + ST InvestmentsLiquidity on hand
$1.0B
$167.6M
Total DebtLower is stronger
$1.8B
$2.8B
Stockholders' EquityBook value
$12.2B
$1.8B
Total Assets
$27.1B
$7.3B
Debt / EquityLower = less leverage
0.15×
1.55×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IVZ
IVZ
OLN
OLN
Q4 25
$1.0B
$167.6M
Q3 25
$973.1M
Q2 25
$922.7M
Q1 25
$821.7M
Q4 24
$986.5M
$175.6M
Q3 24
$1.0B
Q2 24
$878.5M
Q1 24
$895.7M
Total Debt
IVZ
IVZ
OLN
OLN
Q4 25
$1.8B
$2.8B
Q3 25
$1.6B
$3.0B
Q2 25
$1.9B
$3.0B
Q1 25
$964.8M
$3.0B
Q4 24
$890.6M
$2.7B
Q3 24
$890.3M
$2.8B
Q2 24
$890.1M
$2.8B
Q1 24
$1.3B
$2.7B
Stockholders' Equity
IVZ
IVZ
OLN
OLN
Q4 25
$12.2B
$1.8B
Q3 25
$14.0B
$2.0B
Q2 25
$13.9B
$2.0B
Q1 25
$14.7B
$2.0B
Q4 24
$14.6B
$2.0B
Q3 24
$14.8B
$2.1B
Q2 24
$14.6B
$2.1B
Q1 24
$14.6B
$2.2B
Total Assets
IVZ
IVZ
OLN
OLN
Q4 25
$27.1B
$7.3B
Q3 25
$28.4B
$7.6B
Q2 25
$28.5B
$7.7B
Q1 25
$28.1B
$7.7B
Q4 24
$27.0B
$7.6B
Q3 24
$27.5B
$7.5B
Q2 24
$27.2B
$7.7B
Q1 24
$28.1B
$7.6B
Debt / Equity
IVZ
IVZ
OLN
OLN
Q4 25
0.15×
1.55×
Q3 25
0.12×
1.52×
Q2 25
0.14×
1.52×
Q1 25
0.07×
1.50×
Q4 24
0.06×
1.34×
Q3 24
0.06×
1.34×
Q2 24
0.06×
1.31×
Q1 24
0.09×
1.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IVZ
IVZ
OLN
OLN
Operating Cash FlowLast quarter
$455.8M
$321.2M
Free Cash FlowOCF − Capex
$432.2M
FCF MarginFCF / Revenue
25.5%
Capex IntensityCapex / Revenue
1.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.4B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IVZ
IVZ
OLN
OLN
Q4 25
$455.8M
$321.2M
Q3 25
$606.2M
$26.7M
Q2 25
$547.9M
$212.3M
Q1 25
$-84.6M
$-86.0M
Q4 24
$316.9M
$141.7M
Q3 24
$438.4M
$189.9M
Q2 24
$489.1M
$90.6M
Q1 24
$-54.4M
$81.0M
Free Cash Flow
IVZ
IVZ
OLN
OLN
Q4 25
$432.2M
Q3 25
$586.4M
$-44.4M
Q2 25
$530.4M
Q1 25
$-108.0M
$-147.4M
Q4 24
$309.9M
$90.7M
Q3 24
$410.0M
$146.6M
Q2 24
$462.4M
$34.1M
Q1 24
$-75.4M
$36.7M
FCF Margin
IVZ
IVZ
OLN
OLN
Q4 25
25.5%
Q3 25
35.7%
-2.6%
Q2 25
35.0%
Q1 25
-7.1%
-9.0%
Q4 24
19.5%
5.4%
Q3 24
27.1%
9.2%
Q2 24
31.2%
2.1%
Q1 24
-5.1%
2.2%
Capex Intensity
IVZ
IVZ
OLN
OLN
Q4 25
1.4%
Q3 25
1.2%
4.2%
Q2 25
1.2%
Q1 25
1.5%
3.7%
Q4 24
0.4%
3.1%
Q3 24
1.9%
2.7%
Q2 24
1.8%
3.4%
Q1 24
1.4%
2.7%
Cash Conversion
IVZ
IVZ
OLN
OLN
Q4 25
Q3 25
1.70×
0.61×
Q2 25
2.78×
Q1 25
-0.49×
-71.67×
Q4 24
1.51×
14.03×
Q3 24
7.97×
Q2 24
3.70×
1.25×
Q1 24
-0.38×
1.69×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IVZ
IVZ

Investment Advice$1.2B73%
Distribution And Shareholder Service$382.7M23%
Financial Service Other$51.0M3%
Investment Performance$28.9M2%

OLN
OLN

Chlorinechlorinederivativesandothercoproducts$456.2M27%
Causticsoda$400.2M24%
Militaryandlawenforcement$304.6M18%
Epoxyresins$194.9M12%
Aromaticsandallylics$164.4M10%
Commercial$144.8M9%

Related Comparisons